**Back 1979** Back DJ, Breckenridge AM, Crawford FE, et al. An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. *Contraception*. 1979;20(3):263-273.

**Back 1981** Back DJ, Bates M, Breckenridge AM, et al. The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. *Contraception*. 1981;23(3):229-239.

**Back 1987** Back DJ, Grimmer SF, Rogers S, Stevenson PJ, Orme ML. Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. *Contraception*. 1987;36(4):471-479.

**Balogh 1995** Balogh A, Boerner A, Kuhnz W, Klinger G, Vollanth R, Henschel L. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. *Eur J Clin Pharmacol*. 1995;48(2):161-166.

**Chang 2009** Chang, S. Y., Chen, C., Yang, Z., Rodrigues, A. D. (2009). Further assessment of 17α-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. *Drug Metabolism and Disposition*, 37(8), 1667-1675.

**DrugBank DB00977** (https://www.drugbank.ca/drugs/DB00977)

**Ezuruike 2018** Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K. Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. *Clin Pharmacol Ther*. 2018;104(6):1229-1239

**FDA. QUARTETTE** FDA. QUARTETTE (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets, for oral use. Website: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204061s000lbl.pdf

**Goebelsmann 1986** Goebelsmann U, Hoffman D, Chiang S, Woutersz T. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. *Contraception*. 1986;34(4):341-351.

**Granfors 2005** Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. *Clin Pharmacol Ther*. 2005;78(4):400-411.

**Karjalainen 2008** Karjalainen, M. (Thesis, 2008). Inhibition of CYP1A2-mediated drug metabolism in vitro and in humans: With special emphasis on rofecoxib and other NSAIDs. Website: https://helda.helsinki.fi/bitstream/handle/10138/23039/inhibiti.pdf?sequence=1&origin=publication_detail

**Kothare 2012** Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. *BMC Clin Pharmacol*. 2012;12:8. 

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Kuhnz 1996** Kuhnz W, Humpel M, Biere H, Gross D. Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. *Eur J Clin Pharmacol*. 1996;50(3):231-235.

**Martin 2016** Martin P, Gillen M, Ritter J, et al. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. *Drugs R D*. 2016;16(1):93-107.

**Orme 1991** Orme M, Back DJ, Ward S, Green S. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. *Contraception*. 1991;43(4):305-316.

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**Sidhu 2006** Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. *Br J Clin Pharmacol*. 2006;61(2):191-199.

**SmPC Namuscla** SmPC Namuscla 167 mg hard capsules, 2019, website https://www.medicines.org.uk/emc/product/9838/smpc

**Stanczyk 1983** Stanczyk FZ, Mroszczak EJ, Ling T, et al. Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women. *Contraception*. 1983;28(3):241-251.

**Stanczyk 2013** Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. *Contraception*. 2013;87(6):706-727.

**Stockis 2014** Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: A randomized, double-blind, placebo-controlled study. *Epilepsia*. 2014;55(3):27-31.

**Study c13608215-02** Study c13608215. A study to investigate the pharmacokinetic drug-drug interaction following oral administration of ethinylestradiol/levonorgestrel (Microgynon®) and BI 409306 in healthy Korean premenopausal female subjects (an open-label, two-period, fixed-sequence study).” Boehringer Ingelheim Pharma, 06-Aug-2018.

**Timmer 2000** Timmer C, Mulders T. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined vaginal ring. *Clin Pharmacokinet*. 2000;39(3):233-242.

**Wang 2004** Wang, B., Sanchez, R.I., Franklin, R.B., Evans, D.C.,Huskey, S.E. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. *Drug Metab. Dispos*. 32, 1209–1212 (2004).

**Wiesinger 2015**  Wiesinger, H. et al. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. *Br. J. Clin. Pharmacol*. 80, 1399–1410 (2015).

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn* 2007, 34(3): 401-431.

**Zanaflex prescribing information**  Zanaflex prescribing information. Website: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020397s021,021447s002lbl.pdf , 2006, Acorda Therapeutics Inc

**Zhang 2017** Zhang C, Li H, Xiong X, et al. An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch. *Drug Des Devel Ther*. 2017;11:725-731.